The subcutaneous implantable cardioverter–defibrillator (ICD) was designed to avoid complications related to the transvenous ICD lead by using an entirely extrathoracic placement. Evidence comparing ...

Please provide your email address to receive an email when new articles are posted on . Patients with scar-related ventricular tachycardia (VT) who received VT ablation plus a subcutaneous ICD had ...

The FDA today approved the Subcutaneous Implantable Defibrillator (S-ICD) system from Cameron Health. The device is the first ICD that does not require a lead that connects directly to the heart and ...

The Subcutaneous Implantable Cardioverter‑Defibrillator System Post Approval Study (S‑ICD PAS), which observed patients with subcutaneous implantable cardioverter-defibrillators (S‑ICDs) for 5 years, ...

Please provide your email address to receive an email when new articles are posted on . Subcutaneous implantable cardioverter defibrillators can prevent arrhythmic death for people with congenital ...

Implantable cardioverter-defibrillators (ICDs) reduce mortality in patients with increased risk of sudden cardiac death, but use of these devices has been limited by complications with the ...

NICE, FRANCE – A longer-term assessment of a new subcutaneous implantable cardioverter defibrillator (ICD) (Boston Scientific) shows that just over 90% of patients are free from complications at two ...

For older patients without an indication for pacing, the subcutaneous implantable cardioverter-defibrillator (S-ICD; Boston Scientific) provides results comparable to those seen with traditional ...

Cardiac implantable electronic devices (CIEDs) constitute a major breakthrough in the management of heart rhythm disorders. These devices largely include bradycardia pacemakers, biventricular ...

BOSTON -- A leadless pacemaker reliably communicated with a subcutaneous implantable cardioverter-defibrillator (S-ICD) to deliver anti-tachycardia (ATP) and bradycardia pacing, the MODULAR ATP study ...

MARLBOROUGH, Boston Scientific has initiated a worldwide study to evaluate the rate and causes of shocks for patients implanted with the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) for ...

SILVER SPRING, Md.--(BUSINESS WIRE)--Aziyo Biologics, Inc., a fully integrated regenerative medicine company, today announced the launch of a new CanGaroo Bio Envelope specifically for use with ...